BR0308403A - Method for treating an eye disorder of a human or veterinary patient, and using a compound - Google Patents

Method for treating an eye disorder of a human or veterinary patient, and using a compound

Info

Publication number
BR0308403A
BR0308403A BR0308403-5A BR0308403A BR0308403A BR 0308403 A BR0308403 A BR 0308403A BR 0308403 A BR0308403 A BR 0308403A BR 0308403 A BR0308403 A BR 0308403A
Authority
BR
Brazil
Prior art keywords
corneal
eye
urea
compound
guanidinium
Prior art date
Application number
BR0308403-5A
Other languages
Portuguese (pt)
Inventor
Vicken Karageozian
David Castillejos
John Park
Gabriel Arthuro Carpio Aragon
Jose Luis Gutierres Flores
Original Assignee
Vitreo Retinal Technologies In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitreo Retinal Technologies In filed Critical Vitreo Retinal Technologies In
Publication of BR0308403A publication Critical patent/BR0308403A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODO PARA TRATAMENTO DE UM DISTúRBIO DO OLHO DE UM PACIENTE HUMANO OU VETERINáRIO, E, USO DE UM COMPOSTO". Métodos e preparações para tratamento de distúrbios do olho e/ou dissolução de proteoglicanos da córnea, cicatrização organizada do estroma corneal, amolecimento da córnea para correção refrativa não cirúrgica da vista, remoção de névoa e opacificação corneal, inibição de fibroblastos e prevenção de fibrose corneal e formação de cicatrizes, tratamento de pterígios, tratamentos de neovascularização corneal e neovascularização da íris. São admistradas ao olho, em montantes terapeuticamente eficazes, preparações contendo a) uréia, b) derivados de uréia (por exemplo, hidroxiuréia, tiouréia), c) antimetabólitos, e) uréia, derivados de uréia, proteínas não enzimáticas, nucleosídeos, nucleotídeos e seus derivados (por exemplo, adenina, adenosina, citosina, citadina, guanina, guanitadina, guanidínio, cloreto de guanidínio, sais de guanidínio, timidina, timitadina, uradina, uracila, cisteína), ácido tióctico reduzido, ácido úrico, acetil salicilato de cálcio, sulfato de amónio, álcool isopropílico, etanol, polietileno glicol, polipropileno glicol ou outro composto capaz de causar dissolução não enzimática dos proteoglicanos da córnea ou f) quaisquer das combinações possíveis dos mesmos."METHOD FOR TREATMENT OF A DISTURBANCE OF THE EYE OF A HUMAN OR VETERINARY PATIENT, AND USE OF A COMPOUND." Methods and preparations for treating eye disorders and / or corneal proteoglycan dissolution, organized corneal stroma healing, corneal softening for non-surgical refractive eye correction, corneal fogging and opacification, fibroblast inhibition and corneal fibrosis prevention and scar formation, pterygium treatment, corneal neovascularization and iris neovascularization treatments. Therapeutically effective amounts are administered to the eye, preparations containing a) urea, b) urea derivatives (eg hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and its derivatives (e.g. adenine, adenosine, cytosine, citadine, guanine, guanitadine, guanidinium, guanidinium chloride, guanidinium salts, thymidine, thymidadine, uradine, uracil, cysteine), reduced thioctic acid, uric acid, calcium acetyl salicylate , ammonium sulfate, isopropyl alcohol, ethanol, polyethylene glycol, polypropylene glycol or other compound capable of causing non-enzymatic dissolution of the corneal proteoglycans or f) any of the possible combinations thereof.

BR0308403-5A 2002-03-14 2003-03-14 Method for treating an eye disorder of a human or veterinary patient, and using a compound BR0308403A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36397902P 2002-03-14 2002-03-14
PCT/US2003/007700 WO2003077898A1 (en) 2002-03-14 2003-03-14 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye

Publications (1)

Publication Number Publication Date
BR0308403A true BR0308403A (en) 2005-01-18

Family

ID=28041849

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308403-5A BR0308403A (en) 2002-03-14 2003-03-14 Method for treating an eye disorder of a human or veterinary patient, and using a compound

Country Status (10)

Country Link
EP (1) EP1482922A4 (en)
JP (1) JP2005522464A (en)
KR (1) KR20040094793A (en)
CN (1) CN1642536A (en)
AU (2) AU2003213858A1 (en)
BR (1) BR0308403A (en)
CA (1) CA2478965A1 (en)
MX (1) MXPA04008776A (en)
RU (1) RU2363459C2 (en)
WO (1) WO2003077898A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
CN101231121B (en) * 2007-01-24 2012-06-13 泰州乐金电子冷机有限公司 Pallet stretching-out device for refrigerator
CN102859344A (en) * 2010-03-12 2013-01-02 独立行政法人理化学研究所 Clearing reagent for biological material, and use thereof
US10444124B2 (en) 2011-05-20 2019-10-15 Riken Clarifying reagent for biological materials and use thereof
JP6433901B2 (en) 2013-08-14 2018-12-05 国立研究開発法人理化学研究所 Composition for preparing biological material with excellent light transmittance and use thereof
DE102013110608A1 (en) * 2013-09-26 2015-03-26 Florian Lang Substance for inhibiting tissue calcification, tissue fibrosis and age-associated diseases
CN110237238A (en) * 2019-08-02 2019-09-17 山东省眼科研究所 MANF is promoting the application in corneal injury reparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
IL145226A0 (en) * 1999-03-02 2002-06-30 Vitreo Retinal Technologies In Agents for intravitreal administration to treat or prevent disorders of the eye
ES2325360T3 (en) * 2002-02-13 2009-09-02 Vitreo-Retinal Technologies, Inc. TREATMENT OF OPHTHALMIC DISORDERS USING UREA AND DERIVATIVES OF UREA.

Also Published As

Publication number Publication date
CN1642536A (en) 2005-07-20
WO2003077898A1 (en) 2003-09-25
MXPA04008776A (en) 2005-04-19
CA2478965A1 (en) 2003-09-25
RU2004129761A (en) 2005-06-10
AU2003213858A1 (en) 2003-09-29
JP2005522464A (en) 2005-07-28
KR20040094793A (en) 2004-11-10
EP1482922A4 (en) 2005-06-08
RU2363459C2 (en) 2009-08-10
EP1482922A1 (en) 2004-12-08
AU2009201897A1 (en) 2009-06-04
AU2009201897B2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
DE60039043D1 (en) MEDICINE FOR INTRAVITREAL ADMINISTRATION FOR THE TREATMENT OR PREVENTION OF EYE DISEASES
ES2264197T3 (en) DINUCLEOTIDOS AND ITS USES.
BR9909474A (en) Forms ii, crystalline ev of 5,6-dichloro-2- (isopropylamino) -1-beta-1-ribofuranosyl -1h-benzimidazole, 5,6-dichloro-2- (isopropylamino) -1-beta- ethanol solvate l-ribofuranosyl -1h-benzimidazole, composition, compound, use of 5,6-dichloro-2- (isopropylamino) -1-beta-l-ribofuranosyl -1h-benzimidazole, and processes for the treatment of a viral infection in a and for the production of 5,6-dichloro-2- (isopropylamino) -1-beta-1-ribofuranosyl -1h-benzimidazole
NO943901L (en) Methods and Preparations for the Treatment of Diseases with Interferon While Reducing Side Effects
BRPI0507675A (en) 2&#39;-c-methyl nucleoside derivatives
BR9914097A (en) Compound, use of it, pharmaceutical composition and method of prophylaxis or treatment of a viral infection and process for preparing the compound
TR200200234T2 (en) Tyrosine Protein kinase SYK purine derivatives inhibitors
YU9702A (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
BR0308403A (en) Method for treating an eye disorder of a human or veterinary patient, and using a compound
Cronstein The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism
DK0658110T3 (en) Use of norastemizole for the treatment of allergic rhinitis
BRPI0410050A (en) method of treatment or prophylaxis of psychotic disorders, disorders of intellectual impairment or diseases or conditions in which alpha-nicotinic receptor modulation is beneficial, pharmaceutical composition, method of treatment or prophylaxis of diseases, use of a compound, compound, and , method of preparing a compound
CA2314571A1 (en) Methods and compositions for treating diseases and conditions of the eye
NO20023486L (en) Pyrrole-type compounds, compounds containing compounds and their use in the treatment of cancer and viral diseases
EP0286825A3 (en) Use of 3&#39;-fluro-3&#39; deoxythymidine for the manufacture of a medicament for the treatment of virus infections
DE60011637D1 (en) DIOXOLAN NUCLEOSIDE ANALOGS FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS
DK0500953T3 (en) Potentiator of antineoplastic action and antineoplastic agent
BRPI0410878A (en) benzothiazole derivatives and their uses in the treatment of adenosine a2a receptor-related diseases
CO4940437A1 (en) 2-AMINO-7- (2-HYDROXYETHYLENE 1-SUBSTITUTED) -3,5-DIHIDROPIRRO- LO 3,2-PIRIMIDIN-4-ONAS
Shinkai et al. Valacyclovir
BRPI0016329B8 (en) Substituted bis-indolylmaleimides for inhibiting cell proliferation, their preparation process and their use, as well as pharmaceutical composition.
Srinivas Parthenium dermatitis treated with azathioprine weekly pulse doses
EP3572079B1 (en) Etamsylate for treatment of herpes virus infections
JP2021113161A (en) Agent for treating lesch-nyhan syndrome
JPWO2021108427A5 (en)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/17, A61P 27/02, A61P 41/00

Ipc: A61K 31/17 (2011.01), A61P 27/02 (2011.01), A61P 4

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]